<DOC>
	<DOCNO>NCT01664065</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics Ceftaroline group patient renal disease match healthy subject normal renal function</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Ceftaroline End Stage Renal Disease Patients Matched Healthy Subjects</brief_title>
	<detailed_description>An Open-label , Nonrandomised , Phase I Study Assess Pharmacokinetics Ceftaroline After Intravenous Administration aSingle Dose Ceftaroline Fosamil ( 200 mg ) Patients End-stage Renal Disease Undergoing Haemodialysis Compared Single Dose Ceftaroline Fosamil ( 600 mg )</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Inclusion criterion : Provision sign date , write informed consent prior study specific procedure Male female subject age 18 75 year ( inclusive ) suitable vein cannulation repeat venipuncture Women childbearing potential must negative pregnancy test , nonlactating , use highly effective form birth control 3 month prior enrollment , study , 3 month completion studyrelated proceed Have body mass index ( BMI ) 18 35 kg/m2 weigh 50 110 kg Haematocrit level high 30 % screen baseline treatment period Exclusion criterion : History presence gastrointestinal , hepatic , condition know interfere absorption , distribution , metabolism , excretion drug Any clinically significant abnormality clinical chemistry , haematology , urinalysis result , judged investigator Any clinically important abnormality rhythm , conduction , morphology rest ECG may interfere interpretation QTc interval change History clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study Receiving dialysis treatment intermittent haemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Patient Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>